 After screening on Day OR 1, participants initiated luteal support supplementation with vaginal progesterone, which continued throughout the trial. On Day OR 2, participants were randomised to either barusiban, atosiban or placebo and participants received an intravenous IV bolus followed by an IV infusion of either barusiban, atosiban or placebo for approximately 4h. A mock embryo transfer was performed 3h after start of dosing. 